HARARE, ZIMBABWE – The Medicines Control Authority of Zimbabwe (MCAZ) has issued an urgent notification regarding a Class II recall for Azithromycin 500mg USP Tablets due to quality concerns that may impact treatment efficacy.
The recall is directed at all healthcare professionals, pharmaceutical stakeholders, and the general public. The specifics of the affected product are as follows:
Product: Azithromycin 500mg USP Tablets
Batch Number: 24050191
Manufacturer: Indoco Remedies Limited, India
Recall Level: Up to the retail level (Pharmacies and Clinics)
Reason for Recall
The manufacturer initiated a voluntary notification following an out-of-specification (OOS) result during dissolution testing.
This defect was detected during a 24-month stability study. Failure to meet dissolution standards means the medicine may not release the active ingredient properly in the body, potentially leading to
Treatment Failure.
The medicine may not effectively clear bacterial infections leading to antimicrobial resistance. Sub-therapeutic levels of the drug can encourage bacteria to become resistant to future treatment.
In light of this development, the MCAZ Director General, Mr Richard Rukwata emphasized the Authority’s dedication to public safety.
”The Authority remains committed to safeguarding public health by ensuring that all medicines available in Zimbabwe meet the required standards of quality, safety, and efficacy. MCAZ will continue to monitor the recall process and provide updates where necessary,” said Mr. Richard T. Rukwata.
MCAZ requires all
Wholesalers & Healthcare Facilities to immediately quarantine all units of Batch 24050191 and coordinate with Indoco Remedies Limited and local distributors for the return process.
The general public who purchased this specific batch is advised to return it to the pharmacy where it was obtained.
”Patients who has recently consumed tablets from this batch are advised to consult their healthcare professional for further medical guidance,” said Mr Rukwata in the statement.
● Feedback: [email protected]


